非小细胞肺癌不断变化的医疗成本，这意味着什么？ - Suppr | 超能文献

Changing health care costs for NSCLC, what does it mean?

作者信息

Postmus Pieter E

机构信息

Department of Pulmonary Diseases, Leiden University Medical Centre, Leiden, Netherlands.

出版信息

Lung Cancer. 2018 Mar;117:62-63. doi: 10.1016/j.lungcan.2017.11.006. Epub 2017 Nov 11.

DOI:10.1016/j.lungcan.2017.11.006

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Changing health care costs for NSCLC, what does it mean?非小细胞肺癌不断变化的医疗成本，这意味着什么？

Lung Cancer. 2018 Mar;117:62-63. doi: 10.1016/j.lungcan.2017.11.006. Epub 2017 Nov 11.

2

Costs of non-small cell lung cancer in the Netherlands.荷兰非小细胞肺癌的成本。

Lung Cancer. 2016 Jan;91:79-88. doi: 10.1016/j.lungcan.2015.10.015. Epub 2015 Oct 17.

3

A population-based study of the resource utilization and costs of managing resectable non-small cell lung cancer.一项基于人群的可切除非小细胞肺癌管理的资源利用及成本研究。

Lung Cancer. 2014 Nov;86(2):281-7. doi: 10.1016/j.lungcan.2014.09.013. Epub 2014 Sep 20.

4

Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry.TNM-7时代IIIB期非小细胞肺癌的治疗模式与结局：荷兰癌症登记处的结果

Lung Cancer. 2017 Aug;110:14-18. doi: 10.1016/j.lungcan.2017.05.015. Epub 2017 May 18.

5

A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population.中国汉族人群非小细胞肺癌中ALK重排与EGFR突变的大规模横断面研究。

Sci Rep. 2014 Dec 1;4:7268. doi: 10.1038/srep07268.

6

Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.吉非替尼或卡铂-紫杉醇治疗的非小细胞肺癌（NSCLC）患者中表皮生长因子受体（EGFR）突变检测的成本效益分析

Eur J Health Econ. 2016 Sep;17(7):855-63. doi: 10.1007/s10198-015-0726-5. Epub 2015 Sep 4.

7

Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer.非小细胞肺癌患者致癌状态与静脉血栓栓塞风险的关系。

Respir Res. 2018 May 9;19(1):88. doi: 10.1186/s12931-018-0791-2.

8

Changing costs of metastatic non small cell lung cancer in the Netherlands.荷兰转移性非小细胞肺癌的成本变化

Lung Cancer. 2017 Dec;114:56-61. doi: 10.1016/j.lungcan.2017.10.005. Epub 2017 Oct 13.

9

Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients.荷兰非小细胞肺癌患者的治疗趋势及相对生存率（1990 - 2014年）：年轻患者与老年患者之间的差异

Lung Cancer. 2017 Jun;108:198-204. doi: 10.1016/j.lungcan.2017.04.005. Epub 2017 Apr 10.

10

Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.美国医疗保险转移性鳞状非小细胞肺癌患者的真实世界治疗模式和费用。

Lung Cancer. 2015 Feb;87(2):176-85. doi: 10.1016/j.lungcan.2014.11.002. Epub 2014 Nov 8.

引用本文的文献

1

Epidemiology, Patients' Journey and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Evidence Analysis in Italy.早期非小细胞肺癌的流行病学、患者就医过程及医疗费用：意大利的一项真实世界证据分析

Pharmaceuticals (Basel). 2023 Feb 27;16(3):363. doi: 10.3390/ph16030363.

2

Overexpression of golgi membrane protein 1 promotes non-small-cell carcinoma aggressiveness by regulating the matrix metallopeptidase 13.高尔基体膜蛋白1的过表达通过调节基质金属肽酶13促进非小细胞癌的侵袭性。

Am J Cancer Res. 2018 Mar 1;8(3):551-565. eCollection 2018.